Skip to main content
CHRS logo

Coherus Oncology, Inc. (CHRS) Stock Price & Analysis

Coherus Oncology, Inc. (CHRS) — MoonshotScore 18/100 (Weak band), calculated Nov 22, 2026. Price $0.3698 (-4.47%), as of the Nov 20, 2026 trading session; market cap $57.2M.

Educational signal · not a buy or sell recommendation · How to read this

$0.3698 −$0.0173 (-4.47%) Market Cap $57.2M

Coherus Oncology, Inc. · CHRS · NASDAQ

Coherus Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing immunotherapies for cancer treatment. With a strong pipeline of biosimilars and novel therapies, it aims to address significant unmet medical needs in oncology.

Price as of Nov 20, 2026

Key Statistics

18 of 100

MoonshotScore v2 · Coherus Oncology (CHRS)

Weak
Business Quality Poor (17)
Financial Safety Fragile (7)
Valuation Bubble (7)
Growth Durability Shrinking (8)
Momentum Slipping (20)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Slipping.

  • quarterly revenue $14M (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 3 of the last 8 reports
  • Altman Z -14.13 · Piotroski F 3

Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CHRS (58 recorded, newest six shown)
RecordedScoreBand
15Weak
16Weak
16Weak
16Weak
16Weak
16Weak

The score moved from 16 in the stored Nov 21, 2026 snapshot to 18 in the current publication computed Nov 22, 2026 (+2); the largest pillar moves were Valuation +2 and Business Quality +1. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.3698
Change on the day-4.47%
52-week range$0.3698 – $2.62
Market capitalisation$57.2M—
Price / earnings (trailing)1.29
Shares traded on the day2.52M

Price & events

Other perspectives

Council score for Coherus Oncology (CHRS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Negative
Valuation Negative
Growth Durability Negative
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 13, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Weak
ROE Negative
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Coherus Oncology (CHRS), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Coherus Oncology, Inc. (CHRS) is listed on NASDAQ. It employs 145 people and is led by Dennis Lanfear. In Q3 FY2026 it reported revenue of $14M and net income of -$39M. The market values it at $57.2M.

2 · Latest results

What do the latest results show for Coherus Oncology (CHRS)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $14M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$14M-$39M-$0.25 (diluted)
Q2 FY2026$14M-$21M-$0.13 (diluted)
Q1 FY2026$12M-$38M-$0.28 (diluted)
Q4 FY2025$13M-$37M-$0.31 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Coherus Oncology (CHRS)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -14.13 · Piotroski F 3. Trailing ratios: ROA -26.4% · current ratio 1.51.

Data-derived red flags

  • Listing risk — at $0.3698 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -14.13 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
5 · Peer comparison

How does Coherus Oncology compare with its peers?

Short answer

Coherus Oncology's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Regeneron Pharmaceuticals, Inc. (REGN) Named competitor$920.69 Nov 20, 2026$95.2B95 5-pillar Nov 22, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.09 Nov 20, 2026$462M92 5-pillar Nov 22, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 22, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 22, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M87 5-pillar Nov 22, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.80 Nov 20, 2026$120B85 5-pillar Nov 22, 2026
Amgen Inc. (AMGN) Named competitor$435.64 Nov 20, 2026$236B84 5-pillar Nov 22, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.47 Nov 20, 2026$83.3M82 5-pillar Nov 22, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 22, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.57 Nov 20, 2026$155M72 5-pillar Nov 22, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M70 5-pillar Nov 22, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 22, 2026
Coherus Oncology (CHRS) — this page$0.3698$57.2M18

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 5, 2026

Transactions
40
Identified insiders
9
Purchases
0
Sales
0
Other transactions
40

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CHRS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CHRS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Coherus Oncology (CHRS)?

Read these with our analysis →

Common Questions About CHRS

These answers are editorial: 1 of these 9 answers is drawn from the CHRS research dossier (written May 10, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for CHRS?

CHRS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Coherus Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing immunotherapies for cancer treatment.

Is CHRS a good stock to buy?

Stock Expert AI does not rate CHRS buy, sell or hold. Coherus Oncology, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CHRS stock price today?

The last price recorded for Coherus Oncology, Inc. (CHRS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for CHRS?

Coherus Oncology, Inc. faces several risks, including intense competition from established players in the biotechnology sector, which could pressure market share and pricing.

What are the key factors to evaluate for CHRS?

Coherus Oncology, Inc. (CHRS) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Coherus aims to leverage this growth by increasing market penetration and expanding its distribution channels, potentially leading to significant revenue growth over the next few years. Not financial advice.

How frequently does CHRS data refresh on this page?

CHRS's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CHRS's recent stock price performance?

Coherus Oncology, Inc. (CHRS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product pipeline with multiple biosimilars and novel therapies. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CHRS overvalued or undervalued right now?

The trailing P/E of Coherus Oncology, Inc. (CHRS) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of CHRS?

Fractional-share availability for Coherus Oncology, Inc. (CHRS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 9 from Financial Modeling Prep (FMP), 7 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.